Atovaquone - GSK
Alternative Names: 566C; 566C80; BW 566C; BW A566C; BW A566C80; Mepron; Mepron Suspension; Samtirel; Wellvole; WellvoneLatest Information Update: 10 Jul 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiprotozoals; Naphthoquinones
- Mechanism of Action Electron transport complex I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pneumocystis pneumonia
- Discontinued Malaria; Toxoplasmosis
Most Recent Events
- 17 Apr 2012 Launched for Pneumocystis pneumonia (treatment and prevention) in Japan (PO; suspension)
- 18 Jan 2012 Registered for Pneumocystis pneumonia (treatment and prevention) in Japan (PO)
- 29 Dec 2000 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline